Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Oral Posaconazole Prophylaxis for Invasive Fungal Infection

What this Trial Is About

Researchers are studying how the body processes Posaconazole, an oral antifungal medicine given as a preventive treatment to patients undergoing cancer therapies, including chemotherapy or stem cell transplants. This study focuses on patients receiving Posaconazole to prevent invasive fungal infections during their cancer treatment, aiming to better understand the medicine's behavior in these settings. Participants will take Posaconazole tablets, usually 300mg once daily, as part of their standard care. The treatment duration depends on individual hospital policies but generally starts before or with chemotherapy and continues until the patient's immune system recovers. In stem cell transplant patients, Posaconazole also begins around the transplant time and lasts about three months or longer if needed. Blood samples will be collected on days 7, 14, and 21 after starting Posaconazole, with extra samples taken if patients experience significant diarrhea or other absorption issues. If a patient switches to an intravenous form due to complications, a blood sample will be taken after the last oral dose. During the study, participants will provide blood samples and share clinical information while on Posaconazole and for up to seven days after stopping the drug for infection follow-up. Those diagnosed with fungal infections will be tracked for 30 days to monitor outcomes. Researchers will measure Posaconazole levels in the blood to assess how symptoms like diarrhea or conditions such as graft versus host disease affect the medicine's concentration. The study aims to ensure better dosing and management of Posaconazole in cancer patients at risk of fungal infections.

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants